These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21673540)

  • 21. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
    Nishikubo M; Shimomura Y; Hiramoto N; Sawamura N; Yamaguchi T; Hara S; Ishikawa T
    BMC Nephrol; 2021 May; 22(1):175. PubMed ID: 33980166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The recent past and future of adjuvant therapy for pancreatic cancer.
    Yeo CJ
    Ann Surg Oncol; 2003 Jun; 10(5):488-9. PubMed ID: 12794012
    [No Abstract]   [Full Text] [Related]  

  • 24. Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.
    Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Hagihara A; Iwasa S; Kojima Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):755-61. PubMed ID: 18845521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Detection of Urinary Podocytes from Drug-Induced Glomerular Thrombotic Microangiopathy in Advanced Cancer Patients.
    Usui J; Yokoyama C; Hagiwara M; Hirayasu K; Kojima T; Yoshino T; Nishiyama H; Hara M; Yamagata K
    Clin Lab; 2016 Dec; 62(12):2413-2417. PubMed ID: 28164557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Feasibility and anti-tumor activity of postoperative adjuvant chemotherapy with gemcitabine for resected pancreatic cancer].
    Udaka T; Konishi Y; Waki N; Hayama M; Kubo M; Sogabe O; Maeda H; Mizuta M; Shirakawa K
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):937-40. PubMed ID: 18633220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study.
    Kurtz JE; Kohser F; Négrier S; Trillet-Lenoir V; Walter S; Limacher JM; Untereiner M; Kayitalire L; Jaeck D; Dufour P
    Hepatogastroenterology; 2000; 47(35):1450-3. PubMed ID: 11100374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
    Alberts SR; Schroeder M; Erlichman C; Steen PD; Foster NR; Moore DF; Rowland KM; Nair S; Tschetter LK; Fitch TR
    J Clin Oncol; 2004 Dec; 22(24):4944-50. PubMed ID: 15611509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Gemcitabine in elderly patients with unresectable pancreas cancer].
    Hanada K; Hino F; Amano H; Ooe H; Hirota Y; Sasao S; Obayashi M; Kajiyama G
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2521-5. PubMed ID: 12506475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
    El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA
    J Clin Oncol; 2003 Aug; 21(15):2920-5. PubMed ID: 12885810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer.
    Okusaka T; Ito Y; Ueno H; Ikeda M; Takezako Y; Morizane C; Kagami Y; Ikeda H
    Br J Cancer; 2004 Aug; 91(4):673-7. PubMed ID: 15226765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.
    Nishimura M; Toyoda M; Takenaka K; Imamura Y; Chayahara N; Kiyota N; Mukohara T; Kotake T; Tsuji A; Saito K; Saito Y; Minami H
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1165-70. PubMed ID: 27100735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hemolytic-uremic syndrome associated with gemcitabine use: report of one case].
    Vega J; Parodi C; Méndez GP; Goecke H
    Rev Med Chil; 2013 Jun; 141(6):797-802. PubMed ID: 24121585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
    Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
    Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine-induced hepatitis in a pancreatic cancer patient receiving adjuvant therapy following metastasectomy.
    Saadati H; Peccerillo J; Kaley K; Schilsky ML; Saif MW
    JOP; 2009 Sep; 10(5):573-5. PubMed ID: 19734642
    [No Abstract]   [Full Text] [Related]  

  • 36. It's what's inside that counts.
    Shewach DS; Lawrence TS
    J Clin Oncol; 2003 Sep; 21(18):3383-4. PubMed ID: 12885832
    [No Abstract]   [Full Text] [Related]  

  • 37. [Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
    Jiang Y; Zhong H; He P; Zheng L; Yang K
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):472-5. PubMed ID: 26463154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
    El-Rayes BF; Philip PA; Sarkar FH; Shields AF; Ferris AM; Hess K; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA; Abbruzzese JL
    Invest New Drugs; 2011 Aug; 29(4):694-9. PubMed ID: 20107864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
    Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
    Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.
    Pericay Pijaume C; Escudero Emperador P; Bastús Piulats R; Campos Cervera JM; Esquerdo Galiana G; Gallén Castillo M; Alfaro Gamero J; Dotor Navarro E; Pisa Gatell A; Guasch Jordán I; Saigí Grau E;
    Clin Transl Oncol; 2011 Jan; 13(1):61-6. PubMed ID: 21239357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.